

 Phone:
 888-558-5227

 651-644-8424

 Fax:
 888-558-7329

 Email:
 getinfo@lktlabs.com

 Web:
 lktlabs.com

Product Information

Product ID	G5772		
CAS No.	145781-92-6		
Chemical Name Synonym		Pyr-His-Trp-Ser-Tyr-D-Ser(tBu)- Leu-Arg-Pro-AzaGly-NH ₂	
Formula Formula Wt. Melting Point		Bulk quanit	ites available upon request
Purity Solubility	Soluble in water (20 mg/mL), DMSO.	Product ID G5772 G5772	Size 1 mg 2.5 mg
Store Temp Ship Temp Description) or luteinizin	g hormone releasing hormone

Description Goserelin acts as a peptide agonist at the gonadotropin-releasing hormone (GnRH) or luteinizing hormone releasing hormone (LHRH) receptor, stimulating release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) and decreasing androgen levels. Goserelin exhibits anticancer chemotherapeutic benefit, inhibiting cell proliferation and tumor growth in cellular and animal models of prostate cancer, likely through indirect activation of PKC and inhibition of EGFR activity. Goserelin also inhibits cell proliferation and tumor growth in cellular and animal models of Akt phosphorylation. In other animal models, goserelin increases bone elongation.

References Detti L, Uhlmann RA, Zhang J, et al. Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice. Fertil Steril. 2014 Jan 23. pii: S0015-0282(13)03460-2. [Epub ahead of print]. PMID: 24462062.

Zhang Y, Ding JX, Tao X, et al. Goserelin can inhibit ovarian cancer proliferation and simultaneously protect ovarian function from cisplatin: an in vitro and in vivo study. J Chemother. 2013 Apr;25(2):96-103. PMID: 23684357.

Wells A, Souto JC, Solava J, et al. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling. Clin Cancer Res. 2002 Apr;8(4):1251-7. PMID: 11948140.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.